Quantcast
Last updated on April 16, 2014 at 17:34 EDT

Latest Anthera Pharmaceuticals Inc. Stories

2012-09-17 02:25:41

HAYWARD, Calif., Sept. 17, 2012 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation and autoimmune disorders, today provided an update on regulatory discussions for the global development of blisibimod. End of Phase 2 discussions with the US Food and Drug Administration (FDA) have been completed and will allow for the submission of Phase 3 protocols and the initiation of registration...

2012-08-07 10:26:18

HAYWARD, Calif., Aug. 7, 2012 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (NASDAQ: ANTH), today announced financial results and business highlights for the quarter ended June 30, 2012. Financial Results: Total operating expenses for the second quarter ended June 30, 2012 were $16.7 million, as compared to $20.1 million for the first quarter ended March 31, 2012. The decrease in operating expenses for the period is related to the reduced clinical activity following the completion of...

2012-08-01 10:25:54

HAYWARD, Calif., Aug. 1, 2012 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation and autoimmune disorders, today announced it will report its unaudited financial results for the second quarter ended June 30, 2012 on Tuesday, August 7, 2012, after the market closes in the United States. About Anthera Pharmaceuticals Anthera Pharmaceuticals is a biopharmaceutical company focused on...

2012-07-24 10:23:47

HAYWARD, Calif., July 24, 2012 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), today announced that it has completed the previously announced underwritten public offering of 33,000,000 shares of its common stock, offered at a price to the public of $1.00 per share. In addition, the Company has sold 4,950,000 shares of its common stock at a price to the public of $1.00 per share pursuant to the underwriters' option to purchase additional shares, resulting in a total...

2012-07-19 02:26:36

HAYWARD, Calif., July 19, 2012 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH) today announced the pricing of an underwritten public offering of 33 million shares of its common stock, offered at a price of $1.00 per share. The Company estimates that the gross proceeds from the offering, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Anthera, will be $33 million. The offering is expected to close on or about July...

2012-07-18 10:26:37

HAYWARD, Calif., July 18, 2012 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. The Company expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering to cover over-allotments, if any. The Company intends to use the net proceeds from the offering for general corporate...

2012-07-16 10:24:50

In the news release, Anthera Pharmaceuticals Provides Additional Data from the Recently Completed PEARL-SC Study of Blisibimod in the Proposed Phase 3 Population, issued 16-Jul-2012 by Anthera Pharmaceuticals, Inc. over PR Newswire, we are advised by the company that in the table, sixth column, fifth row, the value should be +28.9%, rather than +22.9%, as originally issued inadvertently. The complete, corrected release follows: Anthera Pharmaceuticals Provides Additional Data from the...

2012-07-16 02:24:24

HAYWARD, Calif., July 16, 2012 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation and autoimmune disorders, today announced the final set of clinical data from the Phase 2b PEARL-SC study in patients with systemic lupus erythematosus. Final data from the PEARL-SC clinical study with 200mg weekly blisibimod suggest sustained and greater treatment effects versus placebo utilizing 6,...

2012-07-09 10:23:58

HAYWARD, Calif., July 9, 2012 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation and autoimmune disorders, today announced that Paul F. Truex, Anthera's President and Chief Executive Officer, will present the company's corporate overview on Friday, July 13, 2012, at 1:30 pm Eastern Time (10:30 am Pacific Time) during the 7th Annual JMP Securities Healthcare Conference at the...

2012-06-27 14:22:05

HAYWARD, Calif., June 27, 2012 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation and autoimmune disorders, today announced results from the Phase 2b PEARL-SC clinical study in patients with systemic lupus erythematosus. The purpose of the PEARL-SC study was to identify an effective and safe dose for future phase 3 clinical studies and explore key inclusion criteria and clinical...